<code id='9D08BA4570'></code><style id='9D08BA4570'></style>
    • <acronym id='9D08BA4570'></acronym>
      <center id='9D08BA4570'><center id='9D08BA4570'><tfoot id='9D08BA4570'></tfoot></center><abbr id='9D08BA4570'><dir id='9D08BA4570'><tfoot id='9D08BA4570'></tfoot><noframes id='9D08BA4570'>

    • <optgroup id='9D08BA4570'><strike id='9D08BA4570'><sup id='9D08BA4570'></sup></strike><code id='9D08BA4570'></code></optgroup>
        1. <b id='9D08BA4570'><label id='9D08BA4570'><select id='9D08BA4570'><dt id='9D08BA4570'><span id='9D08BA4570'></span></dt></select></label></b><u id='9D08BA4570'></u>
          <i id='9D08BA4570'><strike id='9D08BA4570'><tt id='9D08BA4570'><pre id='9D08BA4570'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:focus    Page View:885
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In